vs
Side-by-side financial comparison of Duolingo, Inc. (DUOL) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
Duolingo, Inc. is the larger business by last-quarter revenue ($295.5M vs $164.7M, roughly 1.8× PTC THERAPEUTICS, INC.). Duolingo, Inc. runs the higher net margin — 11.9% vs -82.0%, a 93.8% gap on every dollar of revenue. On growth, Duolingo, Inc. posted the faster year-over-year revenue change (27.0% vs -22.7%). Duolingo, Inc. produced more free cash flow last quarter ($103.0M vs $-36.6M). Over the past eight quarters, Duolingo, Inc.'s revenue compounded faster (28.7% CAGR vs -11.5%).
Duolingo, Inc. is a leading global edtech firm operating a gamified language learning platform. It offers free and premium self-paced courses for over 40 languages, plus language certification, math learning tools, and literacy programs, serving individual learners, schools and corporate clients worldwide.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
DUOL vs PTCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.5M | $164.7M |
| Net Profit | $35.1M | $-135.0M |
| Gross Margin | 55.5% | — |
| Operating Margin | 8.0% | -43.3% |
| Net Margin | 11.9% | -82.0% |
| Revenue YoY | 27.0% | -22.7% |
| Net Profit YoY | 24.0% | -104.8% |
| EPS (diluted) | $0.72 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.5M | — | ||
| Q4 25 | $282.9M | $164.7M | ||
| Q3 25 | $271.7M | $211.0M | ||
| Q2 25 | $252.3M | $178.9M | ||
| Q1 25 | $230.7M | $1.2B | ||
| Q4 24 | $209.6M | $213.2M | ||
| Q3 24 | $192.6M | $196.8M | ||
| Q2 24 | $178.3M | $186.7M |
| Q1 26 | $35.1M | — | ||
| Q4 25 | $42.0M | $-135.0M | ||
| Q3 25 | $292.2M | $15.9M | ||
| Q2 25 | $44.8M | $-64.8M | ||
| Q1 25 | $35.1M | $866.6M | ||
| Q4 24 | $13.9M | $-65.9M | ||
| Q3 24 | $23.4M | $-106.7M | ||
| Q2 24 | $24.4M | $-99.2M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 72.8% | — | ||
| Q3 25 | 72.5% | — | ||
| Q2 25 | 72.4% | — | ||
| Q1 25 | 71.1% | — | ||
| Q4 24 | 71.9% | — | ||
| Q3 24 | 72.9% | — | ||
| Q2 24 | 73.4% | — |
| Q1 26 | 8.0% | — | ||
| Q4 25 | 15.4% | -43.3% | ||
| Q3 25 | 12.9% | 1.4% | ||
| Q2 25 | 13.2% | -19.5% | ||
| Q1 25 | 10.2% | 82.5% | ||
| Q4 24 | 6.6% | -76.2% | ||
| Q3 24 | 7.0% | -27.7% | ||
| Q2 24 | 10.5% | -21.5% |
| Q1 26 | 11.9% | — | ||
| Q4 25 | 14.8% | -82.0% | ||
| Q3 25 | 107.5% | 7.5% | ||
| Q2 25 | 17.8% | -36.3% | ||
| Q1 25 | 15.2% | 73.7% | ||
| Q4 24 | 6.6% | -30.9% | ||
| Q3 24 | 12.1% | -54.2% | ||
| Q2 24 | 13.7% | -53.1% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.99 | $-1.63 | ||
| Q3 25 | $5.95 | $0.20 | ||
| Q2 25 | $0.91 | $-0.83 | ||
| Q1 25 | $0.72 | $10.04 | ||
| Q4 24 | $0.31 | $-0.85 | ||
| Q3 24 | $0.49 | $-1.39 | ||
| Q2 24 | $0.51 | $-1.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $-205.3M |
| Total Assets | $2.0B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.0B | $1.9B | ||
| Q3 25 | $1.0B | $1.7B | ||
| Q2 25 | $976.2M | $2.0B | ||
| Q1 25 | $884.0M | $2.0B | ||
| Q4 24 | $785.8M | $1.1B | ||
| Q3 24 | $854.4M | $1.0B | ||
| Q2 24 | $888.2M | $1.1B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-205.3M | ||
| Q3 25 | $1.3B | $-155.8M | ||
| Q2 25 | $977.0M | $-206.5M | ||
| Q1 25 | $893.8M | $-185.8M | ||
| Q4 24 | $824.5M | $-1.1B | ||
| Q3 24 | $822.5M | $-1.1B | ||
| Q2 24 | $766.9M | $-980.2M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $2.9B | ||
| Q3 25 | $1.9B | $2.6B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.4B | $2.7B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.2B | $1.8B | ||
| Q2 24 | $1.1B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $105.6M | $-34.3M |
| Free Cash FlowOCF − Capex | $103.0M | $-36.6M |
| FCF MarginFCF / Revenue | 34.9% | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 3.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | $368.4M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $105.6M | — | ||
| Q4 25 | $107.3M | $-34.3M | ||
| Q3 25 | $84.2M | $-66.3M | ||
| Q2 25 | $90.7M | $-58.3M | ||
| Q1 25 | $105.6M | $870.1M | ||
| Q4 24 | $83.3M | $-30.0M | ||
| Q3 24 | $56.3M | $-77.0M | ||
| Q2 24 | $62.4M | $-71.5M |
| Q1 26 | $103.0M | — | ||
| Q4 25 | $96.6M | $-36.6M | ||
| Q3 25 | $79.4M | $-69.7M | ||
| Q2 25 | $89.5M | $-59.6M | ||
| Q1 25 | $104.3M | $868.4M | ||
| Q4 24 | $81.4M | $-33.8M | ||
| Q3 24 | $53.1M | $-77.5M | ||
| Q2 24 | $56.8M | $-78.8M |
| Q1 26 | 34.9% | — | ||
| Q4 25 | 34.1% | -22.3% | ||
| Q3 25 | 29.2% | -33.1% | ||
| Q2 25 | 35.5% | -33.3% | ||
| Q1 25 | 45.2% | 73.8% | ||
| Q4 24 | 38.8% | -15.8% | ||
| Q3 24 | 27.6% | -39.4% | ||
| Q2 24 | 31.9% | -42.2% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 1.4% | ||
| Q3 25 | 1.8% | 1.6% | ||
| Q2 25 | 0.5% | 0.7% | ||
| Q1 25 | 0.6% | 0.1% | ||
| Q4 24 | 0.9% | 1.8% | ||
| Q3 24 | 1.7% | 0.3% | ||
| Q2 24 | 3.1% | 4.0% |
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.56× | — | ||
| Q3 25 | 0.29× | -4.17× | ||
| Q2 25 | 2.02× | — | ||
| Q1 25 | 3.01× | 1.00× | ||
| Q4 24 | 5.99× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 2.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DUOL
| Bookings | $283.5M | 96% |
| Other | $12.0M | 4% |
PTCT
Segment breakdown not available.
